PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fenfluramine→

Fenfluramine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
458-24-2
Molecular formula
C12H16F3N
Molecular weight
231.26 g/mol
Drug class
Serotonergic antiseizure medicineserotonin-releasing agent and 5-HT receptor modulator
Mechanism of action
The precise mechanism by which fenfluramine reduces seizures in Dravet syndrome and Lennox-Gastaut syndrome is not fully established. It enhances serotonergic signalling, including activity at 5-HT receptors, and may also modulate sigma-1 receptor signalling.
Indications / reported uses
  • Treatment of seizures associated with Dravet syndrome in patients aged 2 years and older
  • Treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older; use requires product-specific cardiac monitoring because of valvular heart disease and pulmonary arterial hypertension risks

Sources: US DailyMed — FINTEPLA (fenfluramine) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fenfluramine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fenfluramine Permitted Daily Exposure (PDE) report (the Fenfluramine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fenfluramine Occupational Exposure Limit (OEL) report (the Fenfluramine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.